Alto Neuroscience, Inc.
ANRO
$3.43
$0.020.59%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.46% | -13.06% | -35.52% | -83.60% | -85.04% |
| Total Depreciation and Amortization | 49.56% | 76.29% | 51.79% | 93.65% | 0.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.82% | 19.64% | 159.29% | 348.64% | 112.23% |
| Change in Net Operating Assets | -9.44% | -1,727.06% | 108.56% | 234.05% | 138.33% |
| Cash from Operations | -17.83% | -50.74% | -12.99% | -51.01% | -76.25% |
| Capital Expenditure | 100.00% | 89.29% | -43.75% | -2,237.21% | -529.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 89.29% | -43.75% | -2,237.21% | -529.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -99.86% | 68.97% | -38.53% | 41.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 307.80% | 81.98% | 34.11% | 2,183.33% | -213.83% |
| Cash from Financing | 361.97% | -93.22% | -99.89% | 2,587.76% | -358.82% |
| Foreign Exchange rate Adjustments | 40.00% | -340.00% | 50.00% | -138.89% | 54.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.30% | -106.06% | -143.10% | -47.54% | -81.80% |